Date: 2011-03-16
Type of information:
phase:
Announcement: dosing of the first patients
Company: Vernalis (UK)
Product: V158866 (fatty acid amide hydrolase (FAAH) inhibitor)
Action mechanism:
Disease: pain and other indications
Therapeutic area: CNS diseases
Country:
Trial
details: The double-blind, placebo controlled study investigating single and multiple ascending doses is being conducted in healthy male volunteers. The objective of the study is to identify doses of V158866 that are both safe and well tolerated and to measure the compound’s effect on FAAH activity and endocannabinoid levels.
Latest news: Vernalis has dosed the first subjects in a Phase I trial of V158866, its fatty acid amide hydrolase (FAAH) inhibitor, a novel target with potential application in a wide range of pain and other indications.
